NKTR

Nektar TherapeuticsNasdaqGS:NKTR Stock Report

Market Cap

US$3.0b

7D

3.5%

1Y

-18.1%

Updated

17 Sep, 2021

Data

Company Financials +
NKTR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

NKTR Overview

Nektar Therapeutics operates as a biopharmaceutical company.

Nektar Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nektar Therapeutics
Historical stock prices
Current Share PriceUS$16.51
52 Week HighUS$12.92
52 Week LowUS$26.75
Beta1.44
1 Month Change22.12%
3 Month Change-2.88%
1 Year Change-18.15%
3 Year Change-72.02%
5 Year Change-11.95%
Change since IPO340.27%

Recent News & Updates

Aug 27

Mr. Manipulation Meets Ms. Opportunity At The Nektar Cocktail Party

At first glance, NKTR's 6-month chart looks horrible. Weak-handed retail investors see the chart and run for the hills. The cause of the decline is a first-rate "short & distort" scheme meant to reduce the share price for several reasons. Meanwhile, institutional holders remain rock solid and even increased positions. Conference call "teal leaves" reveal hints of positive study data. Simple math yields a late 2022 share price of $150-$200.

Shareholder Returns

NKTRUS PharmaceuticalsUS Market
7D3.5%-2.6%-0.6%
1Y-18.1%12.1%33.6%

Return vs Industry: NKTR underperformed the US Pharmaceuticals industry which returned 12.1% over the past year.

Return vs Market: NKTR underperformed the US Market which returned 33.6% over the past year.

Price Volatility

Is NKTR's price volatile compared to industry and market?
NKTR volatility
NKTR Beta1.44
Industry Beta0.64
Market Beta1

Stable Share Price: NKTR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: NKTR's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1990718Howard Robinhttps://www.nektar.com

Nektar Therapeutics operates as a biopharmaceutical company. The company researches and develops pipeline of investigational medicines in oncology, immunology, and virology, as well as a portfolio of approved partnered medicines. The company’s products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of non-small cell lung cancer and immuno-oncology; and phase 1B clinical trial to treat COVID-19

Valuation

Is Nektar Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: NKTR ($16.51) is trading below our estimate of fair value ($195.13)

Significantly Below Fair Value: NKTR is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: NKTR is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: NKTR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NKTR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NKTR's PB Ratio (3.4x) is in line with the US Pharmaceuticals industry average.


Future Growth

How is Nektar Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

54.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NKTR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NKTR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NKTR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NKTR's revenue (55.9% per year) is forecast to grow faster than the US market (9.7% per year).

High Growth Revenue: NKTR's revenue (55.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NKTR's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Nektar Therapeutics performed over the past 5 years?

-24.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NKTR is currently unprofitable.

Growing Profit Margin: NKTR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NKTR is unprofitable, and losses have increased over the past 5 years at a rate of 24% per year.

Accelerating Growth: Unable to compare NKTR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NKTR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).


Return on Equity

High ROE: NKTR has a negative Return on Equity (-52.41%), as it is currently unprofitable.


Financial Health

How is Nektar Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: NKTR's short term assets ($1.1B) exceed its short term liabilities ($131.0M).

Long Term Liabilities: NKTR's short term assets ($1.1B) exceed its long term liabilities ($335.4M).


Debt to Equity History and Analysis

Debt Level: NKTR is debt free.

Reducing Debt: NKTR currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NKTR has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if NKTR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Nektar Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NKTR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NKTR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NKTR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NKTR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NKTR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Howard Robin (68 yo)

14.67yrs

Tenure

US$11,241,549

Compensation

Mr. Howard W. Robin has been the Chief Executive Officer and the President of Prime Holdings & Investments Inc. since July 2001. Mr. Robin has been the Chief Executive Officer and President of Nektar Thera...


CEO Compensation Analysis

Compensation vs Market: Howard's total compensation ($USD11.24M) is above average for companies of similar size in the US market ($USD5.28M).

Compensation vs Earnings: Howard's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: NKTR's management team is considered experienced (3.5 years average tenure).


Board Members

Experienced Board: NKTR's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: NKTR insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.7%.


Top Shareholders

Company Information

Nektar Therapeutics's employee growth, exchange listings and data sources


Key Information

  • Name: Nektar Therapeutics
  • Ticker: NKTR
  • Exchange: NasdaqGS
  • Founded: 1990
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.989b
  • Shares outstanding: 183.80m
  • Website: https://www.nektar.com

Number of Employees


Location

  • Nektar Therapeutics
  • 455 Mission Bay Boulevard South
  • San Francisco
  • California
  • 94158
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/17 22:02
End of Day Share Price2021/09/17 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.